MTOR and hepatocellular carcinoma: Indeed, immunosuppression strategies underpinned by mTOR inhibitors have been introduced in numerous institutions as standard clinical practice for HCC-transplanted cases, despite the lack of evidentiary scientific support (De Simone et al., 2017).